Wells Fargo
NVAX icon

Wells Fargo’s Novavax NVAX Stock Holding History

Wells Fargo’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-998,500
Closed -$6.29M – 7294
2025
Q2 		$6.29M Sell
998,500
-786,700
-44% -$5.21M ﹤0.01% 2292
2025
Q1 		$11.4M Buy
+1,785,200
New +$14.8M ﹤0.01% 1754
2024
Q2 		– Sell
-99,300
Closed -$475K – 7290
2024
Q1 		$475K Buy
+99,300
New +$461K ﹤0.01% 3926
2022
Q1 		– Sell
-1,800
Closed -$258K – 7582
2021
Q4 		$258K Buy
+1,800
New +$309K ﹤0.01% 5120

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo's NVAX Position: Q1 2026 in Review

Wells Fargo reduced its Novavax (NVAX) stake by 59% in Q1 2026, selling an estimated $894K and leaving 67,885 shares worth $553K. The position accounts for ﹤0.01% of the portfolio, ranked #4103.

Wells Fargo first reported a position in NVAX in Q3 2013 and has held it in 50 quarters since. The position peaked at $63.7M in Q2 2015. 258 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • Wells Fargo held 67,885 shares of Novavax worth $553K as of Q1 2026.
  • Wells Fargo sold 98,664 Novavax shares in Q1 2026, an estimated $894K.
  • Novavax made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4103 holding.
  • Wells Fargo first reported a position in Novavax in Q3 2013 and has held it in 50 quarters since.
  • Wells Fargo's Novavax position peaked at $63.7M in Q2 2015.
  • 258 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.